Novartis AG ADR (NVS)vsTraws Pharma Inc (TRAW)

NVS

Novartis AG ADR

NYSE

$148.38

-0.99%

HEALTHCARE · Cap: $273.77B

TRAW

Traws Pharma Inc

NASDAQ

$1.45

+2.11%

HEALTHCARE · Cap: $20.76M

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 2070079% more annual revenue ($56.58B vs $2.73M). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).

NVS

Hold

out of 100

Grade: D+

Growth: 3.3Profit: 9.0Value: 3.3Quality: 4.5

Piotroski: 4/9Altman Z: 1.96

TRAW

Avoid

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 3.8

Piotroski: 4/9Altman Z: -90.04

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-62.1%)

Margin of Safety

-62.1%

Fair Value

$91.39

Current Price

$148.38

$56.99 premium

UndervaluedFair: $91.39Overvalued

Intrinsic value data unavailable for TRAW.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS5 strengths · Avg: 9.4/10

Market CapQuality

$273.77B10/10

Mega-cap, among the largest globally

Return on EquityProfitability

35.1%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability

30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability

23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality

$2.87B8/10

Generating 2.9B in free cash flow

TRAW0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

NVS4 concerns · Avg: 2.8/10

Altman Z-ScoreHealth

1.964/10

Grey zone — moderate risk

Debt/EquityHealth

1.223/10

Elevated debt levels

PEG RatioValuation

3.932/10

Expensive relative to growth rate

Revenue GrowthGrowth

-0.7%2/10

Revenue declined 0.7%

TRAW4 concerns · Avg: 3.0/10

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Market CapQuality

$20.76M3/10

Smaller company, higher risk/reward

Profit MarginProfitability

0.0%3/10

0.0% margin — thin

Return on EquityProfitability

-5639.0%2/10

ROE of -5639.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bull Case : TRAW

TRAW has a balanced fundamental profile.

Bear Case : NVS

The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.

Bear Case : TRAW

The primary concerns for TRAW are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

NVS profiles as a declining stock while TRAW is a value play — different risk/reward profiles.

TRAW carries more volatility with a beta of 1.45 — expect wider price swings.

NVS is growing revenue faster at -0.7% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (49/100 vs 23/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. The company is headquartered in Newtown, Pennsylvania.

Compare with Other DRUG MANUFACTURERS - GENERAL Stocks

NVS vs LLY NVS vs JNJ NVS vs ABBV NVS vs MRK NVS vs AZN TRAW vs LLY TRAW vs JNJ TRAW vs ABBV TRAW vs MRK TRAW vs AZN

Want to dig deeper into these stocks?

Full NVS Analysis →Full TRAW Analysis →